Autolus Therapeutics is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.80 – a decrease of 14.89% over the previous week. Autolus Therapeutics employs 463 staff and has a trailing 12-month revenue of around $10.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.80 |
|---|---|
| 52-week range | $2.94 - $7.45 |
| 50-day moving average | $3.95 |
| 200-day moving average | $4.54 |
| Wall St. target price | $10.38 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.95 from 2024-11-19
| 1 week (2024-11-13) | -10.33% |
|---|---|
| 1 month (2024-10-21) | -34.73% |
| 3 months (2024-08-20) | -26.07% |
| 6 months (2024-05-20) | -26.62% |
| 1 year (2023-11-20) | -33.11% |
|---|---|
| 2 years (2022-11-18) | 30.53% |
| 3 years (2021-11-19) | 6.22 |
| 5 years (2019-11-20) | 13.8 |
| Revenue TTM | $10.1 million |
|---|---|
| Gross profit TTM | $-130,860,000 |
| Return on assets TTM | -21.61% |
| Return on equity TTM | -82.2% |
| Profit margin | 0% |
| Book value | $1.79 |
| Market Capitalization | $801 million |
TTM: trailing 12 months
We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $2.94 up to $7.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 2.039. This would suggest that Autolus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. .
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.